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1. INTRODUCTION {#cas14287-sec-0001}
===============

Breast cancer is the most common cancer in women, with an estimated 2.1 million cases diagnosed in 2018. Unfortunately, this number is increasing given the recent dramatic changes in women\'s lifestyle.[1](#cas14287-bib-0001){ref-type="ref"} Breast cancer is a heterogeneous disease with different subtypes.[2](#cas14287-bib-0002){ref-type="ref"}, [3](#cas14287-bib-0003){ref-type="ref"} Breast cancer is usually categorized into three major subtypes, which show distinct characteristics and reflect patient prognosis: hormone receptor (HR)‐positive type (estrogen receptor \[ER\]+/human epidermal growth factor receptor 2 \[HER2\]−), HER2‐positive type (ER−/HER2+) and triple‐negative type (ER−/HER2−).[4](#cas14287-bib-0004){ref-type="ref"}, [5](#cas14287-bib-0005){ref-type="ref"} ER and HER2 status is clinically significant for their possible use in targeted therapies and treatment strategies based on subtyping have yielded favorable outcomes.[5](#cas14287-bib-0005){ref-type="ref"} However, recurrence remains a problem and is a major cause of breast cancer‐related death. Recurrence that occurs within 5 years from the curative treatment is defined as early recurrence. Early recurrence is frequently observed in triple‐negative and HER2‐positive breast cancer, while late recurrence frequently occurs in the HR‐positive type.[5](#cas14287-bib-0005){ref-type="ref"} Regardless of tumor biology or subtype, higher recurrence is observed in young women compared with the elderdly.[6](#cas14287-bib-0006){ref-type="ref"}

The onset of breast cancer among young patients is a major clinical issue.[6](#cas14287-bib-0006){ref-type="ref"}, [7](#cas14287-bib-0007){ref-type="ref"}, [8](#cas14287-bib-0008){ref-type="ref"}, [9](#cas14287-bib-0009){ref-type="ref"} Recurrence in young women has both a personal and social impact, and results in a substantial economic burden for patients.[9](#cas14287-bib-0009){ref-type="ref"}, [10](#cas14287-bib-0010){ref-type="ref"} Because of the higher probability of recurrence, clinicians tend to favor aggressive therapeutic treatment for young women, increasing the burden on the patients.[9](#cas14287-bib-0009){ref-type="ref"} Thus, there is an urgent need for the discovery of novel biomarkers that would allow physicians to determine when to escalate or de--escalate breast cancer treatment, especially in young women.[5](#cas14287-bib-0005){ref-type="ref"}

MicroRNA (miRNA) are small non--coding RNA that bind to complementary sequences on target mRNA, resulting in their silencing. They have been associated with initiation, development and metastasis in various types of cancers.[11](#cas14287-bib-0011){ref-type="ref"}, [12](#cas14287-bib-0012){ref-type="ref"} With respect to breast cancer, it has been shown that miR‐21 and miR‐155 are oncogenic miRNA,[13](#cas14287-bib-0013){ref-type="ref"}, [14](#cas14287-bib-0014){ref-type="ref"} while miRNA of the miR‐200 family and miR‐205 function as tumor suppressors.[15](#cas14287-bib-0015){ref-type="ref"} The use of miRNA for liquid biopsy for diagnosis of breast cancer and early detection of recurrence is clinically relevant.[16](#cas14287-bib-0016){ref-type="ref"}, [17](#cas14287-bib-0017){ref-type="ref"} Previously, we reported that the miRNA profile correlates with prognosis in young women with breast cancer.[18](#cas14287-bib-0018){ref-type="ref"} We showed that early recurrence is correlated with lower expression of miR‐1285‐5p and higher expression levels of miR‐183‐5p and miR‐194‐5p. However, the genetic relationship between breast cancer recurrence and these miRNA remains to be elucidated. miR‐1285 has been linked to cancer since its discovery by sequencing of human embryonic stem cells.[19](#cas14287-bib-0019){ref-type="ref"} miR‐1285 has been reported to inhibit p53 by binding to its 3′‐UTR.[20](#cas14287-bib-0020){ref-type="ref"} Upregulation of miR‐1285 is induced by ionizing radiation.[21](#cas14287-bib-0021){ref-type="ref"} With regard to miR‐1285‐5p, high expression levels of this miRNA have been associated with infiltrative growth of the follicular variant of papillary thyroid carcinoma.[22](#cas14287-bib-0022){ref-type="ref"} Generally, miRNA have a tissue‐specific function and play tumor‐suppressive and oncogenic roles in a context‐dependent manner.[13](#cas14287-bib-0013){ref-type="ref"}, [14](#cas14287-bib-0014){ref-type="ref"}, [15](#cas14287-bib-0015){ref-type="ref"} While miR‐1285‐5p has been identified as a tumor promoter in the development of non--small‐cell lung carcinoma,[23](#cas14287-bib-0023){ref-type="ref"} it has been suggested that miR‐1285‐5p plays a tumor‐suppressive role in renal cell carcinoma.[24](#cas14287-bib-0024){ref-type="ref"} However, the role of miR‐1285‐5p in breast cancer has not yet been clarified.

Our aim was to confirm whether miR‐1285‐5p plays a role in breast cancer progression. In this study, miR‐1285‐5p was found to be involved in cell growth via the inhibition of the transmembrane protein 194A (*TMEM194A*). We analyzed the correlation between miR‐1285‐5p and *TMEM194A*. As miR‐1285‐5p and *TMEM194A* levels were associated with breast cancer survival, our investigation of the role of the miR‐1285‐5p/*TMEM194A* axis provides novel insight into the tumorigenesis of breast cancer.

2. MATERIALS AND METHODS {#cas14287-sec-0002}
========================

2.1. Ethics committee approval {#cas14287-sec-0003}
------------------------------

This study was approved by the internal ethical review board of the National Cancer Center (NCC), Tokyo, Japan (No. 2014‐386).

2.2. Clinical samples {#cas14287-sec-0004}
---------------------

Clinical samples were confirmed as primary breast cancer at the NCC Hospital, Japan. This study used remaining samples from our previous study.[18](#cas14287-bib-0018){ref-type="ref"} Briefly, matched tumor and non--tumor breast epithelial tissues were obtained from formalin‐fixed paraffin‐embedded (FFPE) tissues by laser‐capture microdissection for RNA extraction.

2.3. Cell lines and transfection {#cas14287-sec-0005}
--------------------------------

Four human breast cancer cell lines (MCF‐7, MDA‐MB‐231, HCC1937 and HCC1954) and HEK293 cells were used in this study. Breast cancer cell lines and HEK293 cells were cultured in Gibco RPMI‐1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS and 1% penicillin/streptomycin. For miRNA functional studies, miRNA mimics (miR‐1285‐5p and negative control \[NC\]) were purchased from Ambion (Thermo Fisher Scientific) and miRNA inhibitors (miR‐1285‐5p and NC) from Qiagen. The recombinant plasmid DNA (*TMEM194A* and control) was purchased from OriGene Technologies. The transfection of either siRNA or miRNA (mimic/inhibitor) was accomplished using DharmaFECT1 Transfection Reagent (Horizon), according to the manufacturer\'s instructions. Co--transfection of plasmid DNA and miRNA mimics was performed using Lipofectamine 2000 (Thermo Fisher Scientific), according to the manufacturer\'s instructions.

2.4. RNA isolation and qPCR assay {#cas14287-sec-0006}
---------------------------------

Total RNA from cultured cells were purified using the miRNeasy Kit (Qiagen), and total RNA from FFPE tissues by using the miRNeasy FFPE Kit (Qiagen), respectively. RNA quality was evaluated with Agilent 2100 Bioanalyzer (Agilent Technologies) and a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). The expression of miRNA and mRNA were determined by TaqMan‐based qPCR methods, according to the manufacturer\'s instructions. All gene‐specific and miRNA‐specific primers were purchased from Applied Biosystems (Thermo Fisher Scientific). All qPCR reactions were performed in triplicate. Expression values of miRNA were normalized to miR‐16 for clinical samples, and RNU6B for cultured cells, while expression values of mRNA were normalized by *GAPDH*.

2.5. Microarray analysis {#cas14287-sec-0007}
------------------------

Gene expression for mRNA was analyzed using Agilent Array platform (8 × 60 K, Agilent Technologies), according to the manufacturer\'s protocols. The Gene Expression Omnibus accession number is GSE125824.

2.6. Cell proliferation assay {#cas14287-sec-0008}
-----------------------------

A CCK‐8 assay (Dojindo Molecular Technologies) was performed according to manufacturer\'s instructions. Briefly, 6000 cells/well were seeded in 96‐well plates. One day after seeding, transfection was performed in octuplet. After the CCK‐8 solution was added and incubated for 1 hour, the absorbance was measured with a microplate reader. The same experiments were repeated after a defined incubation period.

2.7. Colony formation assay {#cas14287-sec-0009}
---------------------------

Transfected cells were replaced at a density of 10 000 cells/well in 6‐well plates. The colonies containing at least 10 cells were scored. The colonies resulting from the surviving cells were counted as each defined point.

2.8. Immunoblots {#cas14287-sec-0010}
----------------

Cells were washed with PBS and scraped into M‐PER Mammalian Protein Extraction Reagent (Thermo scientific), according to the manufacturer\'s instructions. The lysates were transferred to a micro centrifuge tube and centrifuged for 10 minutes at 14 000 *g* at 4°C. The protein concentration of the supernatant was determined by Qubit assay (Thermo Fisher Scientific). Protein extracts (20‐30 µg) were boiled in Sample Buffer Solution with 3‐mercapto‐1,2‐propandiol (×4) (FUJIFILM Wako Pure Chemical) at 100°C for 5 minutes then resolved on 7% Mini‐PROTEAN TGX Precast Gels (Bio‐Rad Laboratories) before transfer onto a polyvinylidene fluoride membrane. Membranes were blocked in Blocking One (nacalai tesque). The membranes were incubated for 60 minutes with each primary antibody at room temperature with gentle agitation. The membranes were incubated for 60 minutes with an HRP‐labeled secondary antibodies at room temperature. All membrane were detected using the Western Lightning Plus‐ECL (PerkinElmer) and luminescent images were analyzed using a LuminoImager, LAS‐3000 (Fujifilm). The relative band and the molecular mass relative to standard molecular mass markers were assessed. The following antibodies were used for immunoblots: rabbit anti--SLC30A9 (1:250, Sigma‐Aldrich), rabbit anti--TMEM194A (1:125, Sigma‐Aldrich) and mouse anti--actin (1:2500, Santa Cruz Biotechnology) were used as primary antibodies, and anti--mouse and anti‐rabbit antibodies were used as secondary antibodies (1:2500; affinity purified sheep anti--mouse IgG and 1:1250; affinity purified donkey anti--rabbit IgG, GE Healthcare).

2.9. Luciferase reporter assay {#cas14287-sec-0011}
------------------------------

The recombinant vector was constructed by inserting the sequence of target genes 3′‐UTR into the pEZX‐MT06 vector encoding a luciferase reporter (GeneCopoeia). For luciferase assay, HEK293T cells were co--transfected with either miR‐1285‐5p or NC mimic and the luciferase vector containing wild‐type or mutated 3′‐UTR of the target genes. One day after co--transfection, cells were lysed and measured using a dual luciferase kit (Promega) for firefly and *Renilla* luciferase activity. Relative light units were determined and the data was expressed as the ratio of firefly : *Renilla* luciferase activity.

2.10. Immunofluorescence {#cas14287-sec-0012}
------------------------

Cells were washed in PBS and fixed with 4% paraformaldehyde for 10 minutes, and blocked with 2.5% Normal Horse Serum and 0.003% Triton X‐100 in PBS for 60 minutes. The primary antibodies used were rabbit anti--gamma tubulin (1:500, Abcam) and mouse anti--pericentrin (1:100, Abcam). The primary antibodies were mixed with 0.1% BSA and 0.003% Triton X‐100 in PBS and applied on to the cells overnight at 4°C. After washing with PBS, the secondary antibodies Alexa Flour 488 goat with either anti--rabbit or anti--mouse IgG (Molecular Probes) of dilution ratio 1:2000 and Hochest33258 (Dojindo Molecular Technologies) of dilution ratio 1:200 were applied for 2 hours. Fluorescence was viewed with confocal Microscopy (Olympus), with Water Immersion Objective 1.2 NA 60× lens. Digital images were captured with FLUOVIEW FV10i ver. 2.1 software in a 1024 × 1024 pixel format. For measurement of the distance between centrosomes and the nuclear envelope, at least 200 cells were measured.

2.11. Statistical analyses {#cas14287-sec-0013}
--------------------------

Statistical differences were determined by unpaired two‐tailed Student\'s *t*‐test and Dunnett\'s test using JMP 10 software (SAS Institute). All values are presented as mean ± standard error (SE). The experimental data were considered statistically significant at *P* \< 0.05. For gene set enrichment analysis, a modified form of the Kolmogorov‐Smirnov test was used for calculating the enrichment score.[25](#cas14287-bib-0025){ref-type="ref"}

3. RESULTS {#cas14287-sec-0014}
==========

3.1. miR‐1285‐5p expression levels are lower in breast tumor tissues compared with normal tissues {#cas14287-sec-0015}
-------------------------------------------------------------------------------------------------

In our previous study, we compared the expression levels of miRNA in tumor tissues from patients with breast cancer and with or without early recurrence, to identify novel prognostic biomarkers. We found that lower expression of miR‐1285‐5p in tumor tissues was correlated with poor prognosis.[18](#cas14287-bib-0018){ref-type="ref"} In this study, we first compared the levels of miR‐1285‐5p in tumor tissues and adjacent normal tissues. For this purpose, we used paired samples obtained in a previous study on young women with operable breast cancer (Table [S1](#cas14287-sup-0004){ref-type="supplementary-material"}).[18](#cas14287-bib-0018){ref-type="ref"} By quantitative PCR (qPCR) analysis, we found that, in all cases, the levels of miR‐1285‐5p were significantly lower in the tumor tissues compared with their normal counterparts (Figure [1](#cas14287-fig-0001){ref-type="fig"}A).

![Decreased expression of miR‐1285‐5p in breast cancer. A, miR‐1285‐5p expression levels analyzed using the qPCR analysis in tumor tissues compared with those in the normal tissues (n = 15). The data are presented as the median value with an interquartile range. The expression of miR‐1285‐5p was normalized to that of miR‐16. B, miR‐1285‐5p expression levels among breast cancer cell lines determined using the qPCR analysis. The expression of miR‐1285‐5p was normalized to that of RNU6B. Representative data are mean ± SE of at least three independent experiments. \**P* \< 0.05, \*\*\**P* \< 0.001](CAS-111-395-g001){#cas14287-fig-0001}

To investigate the levels of miR‐1285‐5p in different breast cancer types, we used breast cancer cell lines representative of the three most common breast cancer subtypes. Specifically, we used HR‐positive (MCF‐7), HER2‐positive (HCC1954) and triple‐negative (MDA‐MB‐231) cell lines. We also used triple‐negative HCC1937 cells, derived from primary breast tumor of a young women aged 22. MDA‐MB‐231, HCC1937 and HCC1954 showed significantly lower expression of miR‐1285‐5p than MCF‐7 (Figure [1](#cas14287-fig-0001){ref-type="fig"}B). These results suggested that the decreased expression of miR‐1285‐5p was related to tumor progression and that miR‐1285‐5p inhibition might be correlated with tumor aggressiveness.

3.2. miR‐1285‐5p inhibits breast cancer cell growth {#cas14287-sec-0016}
---------------------------------------------------

To examine the role of miR‐1285‐5p in breast cancer progression, we investigated the effect of miR‐1285‐5p overexpression on cell proliferation. Cell proliferation assays showed that the overexpression of miR‐1285‐5p significantly suppressed cell proliferation (Figure [2](#cas14287-fig-0002){ref-type="fig"}A). The cell proliferation inhibition rates were as follows: MCF‐7, 55.4% (*P* = 0.023); MDA‐MB‐231, 46.6% (*P* = 0.004); HCC1937, 36.1% (*P* = 0.015); and HCC1954, 36.6% (*P* = 0.038). Furthermore, colony formation assays showed that overexpression of miR‐1285‐5p was significantly correlated with a decrease in the number of colonies formed using the four breast cancer cell lines (Figure [2](#cas14287-fig-0002){ref-type="fig"}B and C). However, the inhibition of miR‐1285‐5p did not alter breast cancer cell line proliferation (Figure [S1](#cas14287-sup-0001){ref-type="supplementary-material"}). This might be a consequence of altered expression of miR‐1285‐5p, which already showed extremely low levels in the breast cancer cell lines used in the study.

![Inhibition of cell growth by miR‐1285‐5p. Assessment of miR‐1285 mimic effect on cell growth. A, The results of CCK‐8 assay are shown. The colored lines represent each miRNA mimic‐transfected cells as follows: blue for miR‐1285‐5p and orange for negative control (NC), respectively. B and C, The results of the colony formation assay are shown. Left panels: representative images. Right panels: graphs showing colony numbers. Scale bar, 500 µm. The data are presented as the mean ± SE of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. (Relative abs, Relative absorbance)](CAS-111-395-g002){#cas14287-fig-0002}

3.3. *TMEM194A* and *SLC30A9*, potential targets of miR‐1285‐5p, are associated with poor prognosis {#cas14287-sec-0017}
---------------------------------------------------------------------------------------------------

Next, we performed microarray analysis in MCF‐7, MDA‐MB‐231, HCC1937 and HCC1954 cells to identify miR‐1285‐5p targets. Hierarchical clustering analysis revealed a segregation of cancer cells with or without miR‐1285‐5p overexpression regardless of the subtype (Figure [3](#cas14287-fig-0003){ref-type="fig"}A). The gene set enrichment analysis (GSEA) indicated that various pathways were affected by the overexpression of miR‐1285‐5p (nominal *P*‐value \< 0.05; Table [1](#cas14287-tbl-0001){ref-type="table"}). For instance, the Myc, E2 Factor (E2F) and DNA repair pathways were downregulated upon overexpression of miR‐1285‐5p (Figure [3](#cas14287-fig-0003){ref-type="fig"}B). Both Myc and E2F are involved in growth‐promoting signal transduction pathways.[26](#cas14287-bib-0026){ref-type="ref"}, [27](#cas14287-bib-0027){ref-type="ref"} Therefore, our findings indicated that cancer‐related pathways were inhibited upon overexpression of miR‐1285‐5p, supporting our hypothesis that miR‐1285‐5p may act as a tumor suppressor.

![In silico analysis of miR‐1285‐5p targets. A, Heat map diagram with two‐way hierarchical clustering using 260 genes whose expression levels differed by \>1.5‐fold (*P* \> 0.05) with overexpression of miR‐1285‐5p vs negative control (NC). Each row represents a gene and each column represents breast cancer cell samples transfected with either miR‐1285‐5p mimic (black) or NC mimic (grey). The cancer cell lines are colored as follows: green for MCF‐7, red for MDA‐MB‐231, orange for HCC1937, and blue for HCC1954. The color scale on the right illustrates the relative expression level of each gene across all samples: red and green are expression levels above and below the mean level, respectively. B, Significantly enriched gene sets using the GSEA of four cancer cell lines transfected with mimic (miR‐1285‐5p/NC). NES, normalized enrichment score. C, Flow diagram showing the selection of target genes of miR‐1285‐5p. D, Kaplan‐Meier plots of recurrence‐free survival according to gene expression level (high/low) that were split by the median value (*TMEM194A*; *P* \< 0.001 and *SLC30A9*; *P* = 0.005). E, Kaplan‐Meier plots of overall survival according to gene expression (high/low) that were split by the median value (*TMEM194A*; *P* = 0.019 and *SLC30A9*; *P* = 0.170). HR, hazard ratio](CAS-111-395-g003){#cas14287-fig-0003}

###### 

Gene set enrichment analysis (GSEA) after miR‐1285‐5p overexpression: (A) downregulated gene sets due to the overexpression of miR‐1285‐5p and (B) upregulated gene sets due to the overexpression of miR‐1285‐5p

  \(A\)                                        
  ----------------------- ---- ------- ------- -------
  MYC Targets V1          91   −1.74   0.024   0.049
  DNA repair              70   −1.67   0.031   0.097
  Adipogenesis            82   −1.30   0.032   0.445
  Fatty acid metabolism   67   −1.39   0.045   0.308
  E2F targets             95   −1.59   0.048   0.139

  \(B\)                            
  ------------ ---- ------ ------- -------
  Myogenesis   91   1.24   0.040   1.000

FDR, false discovery rat; NES, normalized enrichment score; NOM, Nominal.

John Wiley & Sons, Ltd

The microarray analysis showed that 23 and 31 genes were upregulated and downregulated, respectively, upon overexpression of miR‐1285‐5p (fold change \>1.5 relative to NC, *P* \< 0.01; Table [S2](#cas14287-sup-0005){ref-type="supplementary-material"}). We narrowed down the putative targets of miR‐1285‐5p (Figure [3](#cas14287-fig-0003){ref-type="fig"}C). We used a computational algorithm (TargetScan) to identify putative miR‐1285‐5p binding sites[28](#cas14287-bib-0028){ref-type="ref"} and found four possible targets: ubiquitin protein ligase E3C (*UBE3C*), *TMEM194A*, eukaryotic translation initiation factor 1A X‐linked (*EIF1AX*) and solute carrier family 30 member 9 (*SLC30A9*).

To evaluate the interaction between these mRNA and miR‐1285‐5p, we assessed their clinical relevance in breast cancer using a public database. Recurrence‐free survival (RFS) and overall survival were determined using the Kaplan‐Meier plotter.[29](#cas14287-bib-0029){ref-type="ref"} Survival curves were analyzed according to the gene expression levels (high/low) of the candidate genes (*UBE3C*, *TMEM194A*, *EIF1AX* and *SLC30A9*). We found that high expression of *SLC30A9* and *TMEM194A* was significantly associated with poor prognosis (Figure [3](#cas14287-fig-0003){ref-type="fig"}D). While there was no correlation between *SLC30A9* expression and overall survival, higher expression of *TMEM194A* was significantly associated with poor overall survival (Figure [3](#cas14287-fig-0003){ref-type="fig"}E). These results suggested that two potential targets of miR‐1285‐5p (*TMEM194A* and *SLC30A9*) might be related to breast cancer development and recurrence.

3.4. miR‐1285‐5p negatively regulates *TMEM194A* expression {#cas14287-sec-0018}
-----------------------------------------------------------

Next, we examined whether *TMEM194A* and *SLC30A9* were directly regulated by miR‐1285‐5p. Whereas overexpression of miR‐1285‐5p decreased the mRNA levels of *TMEM194A* and *SLC30A9* in all cancer cell lines (MCF‐7, MDA‐MB‐231, HCC1937 and HCC1954) (Figure [4](#cas14287-fig-0004){ref-type="fig"}A), immunoblots showed that overexpression of miR‐1285‐5p only inhibited TMEM194A protein levels (Figure [4](#cas14287-fig-0004){ref-type="fig"}B). We evaluated whether miR‐1285‐5p regulated *TMEM194A* or *SLC30A* by binding to their 3′‐UTR using luciferase reporter assays. miR‐1285‐5p has one and two putative biding sites in the 3′‐UTR of *TMEM194A* and *SLC30A9*, respectively (Figure [4](#cas14287-fig-0004){ref-type="fig"}C). Luciferase reporter assays showed that miR‐1285‐5p significantly decreased the luciferase activity of the wild‐type *TMEM194A*‐3′‐UTR and *SLC30A*‐3′‐UTR plasmids (Figure [4](#cas14287-fig-0004){ref-type="fig"}D), while mutation of the predicted binding sites within the 3′‐UTR of both *TMEM194A* and *SLC30A9* abolished the inhibitory effect of miR‐1285‐5p on the luciferase activity (Figure [4](#cas14287-fig-0004){ref-type="fig"}D). These data indicate that, by binding to the 3′‐UTR of *TMEM194A* and *SLC30A9*, miR‐1285‐5p regulates their expression.

![Experimental validation for the interaction between miR‐1285‐5p and *TMEM194A*. A, The qPCR analysis of *TMEM194A* and *SLC30A9* upon overexpression of miR‐1285‐5p. Expression of mRNA was normalized to that of *GAPDH*. The data are mean ± SE of three independent experiments. B, Representative immunoblots for TMEM194A and SLC30A9 upon overexpression of miR‐1285‐5p. C, Wild‐type and mutated type of putative miR‐1285‐5p target sequences of 3′‐UTR of *TMEM194A* and *SLC30A9*. Bold font indicates putative miR‐1285‐5p‐binding sequences. D, The luciferase reporter assay in HEK293T cells co--transfected with miRNA mimics (miR‐1285‐5p/NC) and either wild‐type or mutated type luciferase reporter plasmid. The data are mean ± SE of three measurements. Mut, mutated type; WT, Wild‐type. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001](CAS-111-395-g004){#cas14287-fig-0004}

We investigated whether inhibition of *TMEM194A* and *SLC30A9* could mimic the growth inhibitory effect of *miR‐1285‐5p* in breast cancer cells. For this purpose, we analyzed cell proliferation after knockdown of *TMEM194A* and *SLC30A9* using siRNA. qPCR analysis showed that the expression of both *TMEM194A* and *SLC30A9* was downregulated using two different siRNA for each gene (Figure [5](#cas14287-fig-0005){ref-type="fig"}A and B). Remarkably, *TMEM194A* knockdown significantly inhibited cell growth (Figure [5](#cas14287-fig-0005){ref-type="fig"}C). The cell proliferation inhibition rates of each siRNA were as follows: MCF‐7, 73.8% and 80.4% (*P* \< 0.001 and \<.001); MDA‐MB‐231, 80.7% and 64.7% (*P* \< 0.001 and \<.001); HCC1937, 87.0% and 71.0% (*P* \< 0.001 and \<.001); and HCC1954, 79.1% and 77.1% (*P* = 0.001 and \<.001). Conversely, *SLC30A9* inhibition had no effect (Figure [5](#cas14287-fig-0005){ref-type="fig"}D).

![Inhibition of cell growth by silencing of *TMEM194A*. A and B, Knockdown efficacy of two different siRNA for *TMEM194A* and *SLC30A9* analyzed by qPCR analysis. Expression of mRNA was normalized to that of *GAPDH*. The data are mean ± SE of three independent experiments. C and D, Effects of *TMEM194A* or *SLC30A9* knockdown on cell proliferation. The data are mean ± SE of three independent experiments. Relative abs, Relative absorbance.\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001](CAS-111-395-g005){#cas14287-fig-0005}

Liu *et al* (2019) reported that *TMEM194A* is responsible for tumorigenesis and is essential for tamoxifen resistance in breast cancer cells.[30](#cas14287-bib-0030){ref-type="ref"} Consequently, we attempted to confirm the oncogenic activity of *TMEM194A* by inducing its expression in MCF‐7 cells. We observed that *TMEM194A* overexpression was associated with considerable augmentation of cell proliferation (Figure [6](#cas14287-fig-0006){ref-type="fig"}), which strongly supported the oncogenic role of this gene, at least in breast cancer cells.

Liu *et al* (2019) reported that *TMEM194A* is responsible for tumorigenesis and is essential for tamoxifen resistance in breast cancer cells.[30](#cas14287-bib-0030){ref-type="ref"} Consequently, we attempted to confirm the oncogenic activity of *TMEM194A* by inducing its expression in MCF‐7 cells. We observed that *TMEM194A* overexpression was associated with considerable augmentation of cell proliferation (Figure [6](#cas14287-fig-0006){ref-type="fig"}), which strongly supported the oncogenic role of this gene, at least in breast cancer cells.

![Promotion of cell growth by the overexpression of *TMEM194A*. Assessment of miR‐1285 mimic effect on cell growth. Colored lines represent each co--transfected MCF‐7 cells as follows: blue for Cont plasmid, red for *TMEM194A* plasmid + miR‐1285‐5p, and yellow for *TMEM194A* plasmid + NC, respectively. \*\**P* \< 0.01, \*\*\**P* \< 0.001](CAS-111-395-g006){#cas14287-fig-0006}

3.5. *TMEM194A* functions in separation of centrosomes from the nuclear envelope {#cas14287-sec-0019}
--------------------------------------------------------------------------------

*TMEM194A* is a component of the nuclear envelope (NE). To examine whether there was a connection between *TMEM194A* and the cytoplasmic mechanical systems, we measured the distance between the NE and centrosomes after silencing of *TMEM194A*. Immunofluorescence analysis showed that knockdown of *TMEM194A* caused separation of the centrosomes from the NE (Figure [7](#cas14287-fig-0007){ref-type="fig"}A). This observation was consistent in all cancer cell lines (MCF‐7, MDA‐MB‐231, HCC1937 and HCC1954), which argued for a functional connection between *TMEM194A* and the cytoskeleton. Next, we tested whether this phenotypical change was observed upon overexpression of miR‐1285‐5p. Comparably, miR‐1285‐5p overexpression was associated with centrosome separation (Figure [7](#cas14287-fig-0007){ref-type="fig"}B). Finally, we performed immunostaining of pericentrin to confirm the implication of miR‐1285‐5p and *TMEM194A* in centrosome formation because pericentrin, one of the components of centrosomes, cooperates with dynein for centrosome assembly and mitotic spindle pole formation (Figure [S2](#cas14287-sup-0002){ref-type="supplementary-material"}).

![Separation of centrosomes from the nuclear envelope by *TMEM194A* inhibition. The distance between centrosomes and nuclear envelope (NE), confirmed using immunofluorescence (IF) of ɤ‐tubulin and Hochest33258. Measurement of the distance after either silencing *TMEM194A* expression (A) or overexpressing miR‐1285‐5p (B). The images were taken using the same scale. IF are indicated as follows: blue for Hochest33258 and green for ɤ‐tubulin. \*\*\**P* \< 0.001](CAS-111-395-g007){#cas14287-fig-0007}

4. DISCUSSION {#cas14287-sec-0020}
=============

In this study, we revealed a novel mechanism through which miR‐1285‐5p is involved in cell growth suppression by directly targeting *TMEM194A* in breast cancer. TMEM194A is expressed ubiquitously and is also called nuclear envelope integral membrane protein 1 (Nemp1). In the nucleus, many proteins in the lamina and its bound NE transmembrane proteins (NET) bind chromatin adjacent to the NE, and some of the NET are involved in the regulation of gene expression and genome stability.[31](#cas14287-bib-0031){ref-type="ref"} The NE is a protective barrier for the genome against toxic agents and can affect gene expression through regulation of nuclear pore complexes, which direct the nuclear/cytoplasmic trafficking of proteins.[32](#cas14287-bib-0032){ref-type="ref"} In addition, the NE contributes to proper positioning of the nucleus through cytoplasmic mechanical systems, which direct its movement during processes such as cell migration and invasion, essential for the dissemination of cancer cells.[33](#cas14287-bib-0033){ref-type="ref"}, [34](#cas14287-bib-0034){ref-type="ref"} As a component of the cytoplasmic mechanical systems, centrosomes also contribute to cell polarity and motility.[35](#cas14287-bib-0035){ref-type="ref"}

However, few studies have investigated *TMEM194A* function in this regard. Mamada and colleagues have demonstrated the involvement of *TMEM194A* in the neural development of *Xenopus laevis*.[36](#cas14287-bib-0036){ref-type="ref"} The same group confirmed that TMEM194A localized at the nuclear periphery and reported TMEM194A as a new type of RanGTP‐binding protein.[37](#cas14287-bib-0037){ref-type="ref"} These studies demonstrated that *TMEM194A* regulates gene expression and support our data indicating that the inhibitory effect on proliferation upon overexpression of miR‐1285‐5p might be mediated by *TMEM194A* inhibition. Liu *et al* (2019) suggested involvement of *TMEM194A* for tamoxifen resistance in breast cancer.[30](#cas14287-bib-0030){ref-type="ref"} In line with their study, our data indicated oncogenic roles of *TMEM194A* in MCF‐7 cells (Figure [6](#cas14287-fig-0006){ref-type="fig"}). In addition, we speculate that *TMEM194A* may function as a component of the mechanical system that connects the nucleus with the cytoskeleton. Previously, Buch and colleagues performed similar experiments using a different NET, spindle‐associated membrane protein 1 (*Samp1*), and silencing of *Samp1* expression caused the separation of centrosomes from the NE in HeLa cells.[38](#cas14287-bib-0038){ref-type="ref"} In addition, it has been reported that deficiency of either emerin or lamin A/C results in detachment of centrosomes from the NE.[39](#cas14287-bib-0039){ref-type="ref"}, [40](#cas14287-bib-0040){ref-type="ref"} Centrosomes have a critical function in cell division to separate chromosomes accurately.[34](#cas14287-bib-0034){ref-type="ref"}, [35](#cas14287-bib-0035){ref-type="ref"} Unusual positioning of centrosomes may cause aneuploidy in cancer cells. However, the consequence of the detachment of centrosomes in this study remains unclear. In addition, NE plays a role in cancer biology, and failure to dissemble the NE could result in increase of aneuploidy and lagging chromosome.[31](#cas14287-bib-0031){ref-type="ref"} Although the consequences of unusual positioning of centrosomes remain unclear, dysregulation of *TMEM194A* role in nuclear positioning may contribute to both tumorigenesis and tumor aggressiveness.

We showed the interaction between miR‐1285‐5p and *TMEM194A* using several breast cancer cell lines. However, we could not confirm the correlation between miR‐1285‐5p and *TMEM194A* expression in clinical samples due to the poor quality of the FFPE samples, which had been stored for a long time. In addition, we do not know whether the interaction is specific to young women. In this study, we showed higher expression of miR‐1285‐5p in normal tissues compared with tumor tissues (Figure [1](#cas14287-fig-0001){ref-type="fig"}A, *P* = 0.010). Analysis of a publicly available database (Oncomine Platform[41](#cas14287-bib-0041){ref-type="ref"}) shows higher expression of *TMEM194A* in breast tumor tissues compared with normal tissues (Figure [S3](#cas14287-sup-0003){ref-type="supplementary-material"}, *P* = 0.031). These data indicate the inverse correlation between miR‐1285‐5p and *TMEM194A* and, together with our findings, suggest that *TMEM194A* plays an oncogenic role, regardless of age. We also identified *SLC30A9* as a candidate target of miR‐1285‐5p and demonstrated their direct interaction in luciferase reporter assays, although the inhibitory effect of miR‐1285‐5p on *SLC30A9* expression was relatively low. Chandler and colleagues examined the expression of zinc transporters in several breast cancer cell lines by qPCR and immunoblotting, and showed that a change in the mRNA expression of zinc transporters is not always paralleled by a change in their protein levels.[42](#cas14287-bib-0042){ref-type="ref"} We believe that a similar phenomenon occurs in the case of *SLC30A9.* Furthermore, *SLC30A9* is a nuclear receptor coactivator,[43](#cas14287-bib-0043){ref-type="ref"}, [44](#cas14287-bib-0044){ref-type="ref"}, [45](#cas14287-bib-0045){ref-type="ref"}, [46](#cas14287-bib-0046){ref-type="ref"} also known as human embryonic lung protein (*HUEL*) and GRIP1‐associates coactivator 63 (*GAC63*). The members of the SLC30A family are characterized by six trans‐membrane domains and are important in the export of zinc.[47](#cas14287-bib-0047){ref-type="ref"} However, it has not been elucidated whether *SLC30A9* functions as a zinc transporter. Through a transfection experiment in HEK293 cells, Perez et al (2017) demonstrated that mutant *SLC30A9* show lower zinc concentration compared with wild‐type *SLC30A9*, suggesting that *SLC30A9* might act as a zinc transporter.[48](#cas14287-bib-0048){ref-type="ref"} Breast tumors accumulate abnormally high levels of zinc, which might result in cytotoxicity.[49](#cas14287-bib-0049){ref-type="ref"}, [50](#cas14287-bib-0050){ref-type="ref"} Thus, it may be interesting to elucidate the involvement of *SLC30A9* in zinc homeostasis in breast cancer.

In summary, we showed that miR‐1285‐5*p* regulates *TMEM194A* expression by binding to its 3′‐UTR. miRNA offer great promise for developing new diagnostic markers. However, the elucidation of the functional roles of individual miRNA is necessary for the development of their clinical application. We believe that the findings of the present study deepen our understanding of breast cancer progression and facilitate the development of novel therapeutic strategies.
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